A Phase 4 Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients with Polyneuropathy of Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with a V122I or T60A Mutation
Clinical Trial Information
Trial Contact: Peisner, Pamela
Trial Phone: 321.843.1037
To evaluate the effectiveness of patisiran on
ambulatory status in patients with hATTR
amyloidosis with polyneuropathy who have a
V122I or T60A mutation
1. 18 years or older.
2. Diagnosed with hATTR amyloidosis with polyneuropathy, with a documented V122I or
3. PND score of I-IIIB at the baseline visit (see Section 10.1).